Arbutus Biopharma Corporation ABUS Non-cash interest expense
Non-cash interest expense at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept abus:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's non-cash interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's non-cash interest expense?
- Arbutus Biopharma Corporation (ABUS) reported non-cash interest expense of $17K in Q1 2026.
- How has Arbutus Biopharma Corporation's non-cash interest expense changed year-over-year?
- Arbutus Biopharma Corporation's non-cash interest expense decreased by 39.3% year-over-year, from $28K to $17K.
- What is the long-term trend for Arbutus Biopharma Corporation's non-cash interest expense?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's non-cash interest expense has grown at a -57.3% compound annual growth rate (CAGR), from $2.85M to $95K.
- What does non-cash interest expense mean?
- This represents interest expenses recognized in the income statement that do not require a current cash outlay, often associated with the amortization of debt discounts or financing obligations related to royalty monetization. It is used to reconcile net income to actual cash interest paid. Monitoring this helps assess the true cash burden of the company's financing structure.